ReviewCurrent medical science2021

Combination of CRISPR/Cas9 System and CAR-T Cell Therapy: A New Era for Refractory and Relapsed Hematological Malignancies.

Ke-Jia Hu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.